Primary immune thrombocytopenia (ITP) has been traditionally thought as an antibody-mediated autoimmune disease involving platelet destruction by macrophages in the reticuloendothelia system. More recently it has become obvious that ITP is a more complex disorder in which T cell mediated immunity plays important roles in platelet destruction. Antiplatelet autoantibody production is under the control of platelet-specific helper T-cells, and loss of tolerance to self antigen by T cells is the critical step of the immune dysregulation in ITP. Dendritic cells (DCs) from ITP patients showed enhanced capacity in stimulating autologous T-cell proliferation in the presence of autologous/allogeneic platelets \[[@B1]\], and ITP patients' T cells had elevated IL-2 secretion ability compared with controls \[[@B2],[@B3]\], suggesting increased antiplaltelet T-cell reactivity in ITP. The epitopes that recognize platelet glycoprotein (GP) IIIa on T helper (Th) cells has been determined and mapped by several groups \[[@B4],[@B5]\], thus sheding new lights on the "therapeutic vaccination" approach to reinstate tolerance in ITP. Autoreactive T-cell reactivity against platelet antigen in active ITP patients has been observed at polyclonal as well as oligoclonal levels \[[@B6],[@B7]\]. Our group has demonstrated that blocking the B7-CD28 interaction with CTLA4-Ig/CsA could induce platelet GP-specific T-cell anergy, which could exert suppressive effect on GP-reactive T cells via inducing tolerogenic dendritic cells (DCs) \[[@B8],[@B9]\]. It has been well established that apoptotic genes, such as Fas, A20, Bax, Calpastatin, IL2RB, were expressed aberrantly in patients with active ITP \[[@B10],[@B11]\], leading to autoreactive T cells resistant to activation induced cell death (AICD), which could in turn support the expansion of self-reactive T-cell clones. A loss of resistant to AICD might be an important mechanism for the achievement of remission in ITP. Previous studies have revealed that dexamethasone could suppress T-cell proliferation and induce apoptosis of T-cells in ITP \[[@B11],[@B12]\]. In addition, our group has demonstrated that a novel BAFF blocking reagent, BR3-Fc, could restore the apoptosis of both B and T cells \[[@B13]\]. Th polarization in ITP has been attributed to increased Th1 \[[@B2],[@B14]\], and Th17 cells \[[@B15]\] or reduced number or function of CD4^+^CD25^+^Foxp3^+^ T-regulatory cells (Tregs) \[[@B16],[@B17]\]. A parallel body of aberrant cytokine patterns, such as the elevated ratio of interleukin (IL) -18/IL-18 binding protein (BP) \[[@B18],[@B19]\], the increased expression of B cell activating factor (BAFF) has been reported in active ITP patients \[[@B20],[@B21]\]. High-dose dexamthasone (HD-DXM) could not only restore Th1/Th2 \[[@B14]\] or IL-18/IL-18BP balance \[[@B19]\], but also increase the number of Tregs \[[@B16]\], and inhibit the expression of BAFF \[[@B12]\]. Besides HD-DXM, multiple agents, such as rituximab \[[@B22]\], intravenous immunoglobulin (IVIg) \[[@B23]\], romiplostim, eltrombopag \[[@B24]\] as well as indirubin \[[@B25]\], could increase the number or restore the function of Tregs in ITP. Our recently study showed that GP-specific induced Tregs could be successfully generated de novo from nonregulatory CD4^+^CD25^-^CD45RA^+^ cells and could mediate both antigen-specific and linked suppression of proliferating antiplatelet CD4^+^ Th cells in vitro, and further research revealed that the de novo expanded Tregs mediated their suppressive effects on T cells via actually modulating the T-cell stimulatory capacity of DCs \[[@B26]\], thus providing a clue to the potential of producing antigen-specific Tregs from the patients in vitro for the purpose of antigen-targeted cellular immunotherapy. In conclusion, induction of T-cell tolerance may provide a useful strategy for the management of ITP.
